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ABSTRACT
The anticancer drug cisplatin executes its cytotoxic
activity via formation of intra- and interstrand cross-
links in DNA. The relative contribution of structurally
defined cisplatin adducts to induce apoptosis and
the cellular processing of these lesions is still poorly
understoodmostlyduetothelackofsensitiveanalyt-
ical tools for in vivo studies. Here we describe a
new method to establish and characterize mono-
clonal antibodies (Mab) for structurally defined DNA
adducts.Thetwomajorreactionproductsofcisplatin,
the guanine–guanine (Pt-[GG]) and adenine–guanine
(Pt-[AG]) intrastrand crosslinks are recognized
by Mab R-C18 and R-B3, respectively. Both anti-
bodies were employed in an immuno-cytological
assay allowing the quantification of drug-induced
lesions in individual cell nuclei at clinically relevant
doses. Analyzing various tissues of cisplatin-treated
C57Bl/6micetheaccumulationofPt-(GG)washighest
in kidney tubular cells compared with 30, 50 and 90%
lower levels in kidney stroma, liver and peripheral
blood cells, respectively. Adduct kinetics revealed
that wild type mouse cells remove up to 80% of
the crosslinks in contrast to their complete persist-
ence in nucleotide excision repair-deficient (XPC
 / )
mice. The aptitude of the immunoassay for human
molecular dosimetry studies was demonstrated by
measuring adduct levels in tumor biopsies from
patients treated with cisplatin.
INTRODUCTION
The inorganic platinum (Pt) drugmoleculecisplatin(cis-diam-
minedichloroplatinum [II]), ﬁrst described as an antineoplastic
agent in 1965 by Rosenberg et al. (1), is among the most
frequently used chemotherapeutics for the treatment of a
broad range of solid tumors [reviewed in (2,3)]. The efﬁcacy
of platinum-based chemotherapy is hampered by two major
obstacles, the development of cellular and clinical resistance
[reviewed in (4,5)], leading to therapeutic failure and
dose-limiting side effects like nephro- (6), neuro- (7) or oto-
toxicity (8).
Both, the antineoplastic activity and the dose-limiting tox-
icities of cisplatin result from the formation of reaction pro-
ducts with DNA in target cells. The intracellular exchange of
chloro- to hydroxo-ligands in the molecule initiates a fast
formation of DNA monoadducts preferentially at nucleophilic
N-atoms of purines. This reaction is followed by a comparable
slow conversion into bivalent intra- and interstrand crosslinks
withinhours[reviewedin(9)].Fourdifferentstructures,linked
at the N-7 position of adenines and guanines, have been
identiﬁed: the intrastrand adducts cis-Pt(NH3)2d(pGpG)
(abbreviated as Pt-[GG]), cis-Pt(NH3)2d(pApG) (abbreviated
as Pt-[AG]) and cis-Pt(NH3)2d(pGpXpG), representing >95%
of total DNA platination and the interstrand lesion cis-
Pt(NH3)2d(GMP)2 (10,11). The degree of DNA adduct forma-
tion by cisplatin is cell type-speciﬁc (12) due to a number of
pharmacokinetic parameters like kidney function (13), drug
export by MRP2 membrane transporters (14) or cytoplasmatic
detoxiﬁcation (15). Some of these factors may also contribute
to the observed inter-individual differences in the level of
DNA platination after treatment with cisplatin. The removal
of platinated DNA (Pt-DNA) intrastrand crosslinks has been
linked to nucleotide excision repair (NER) (16,17) and to the
NER sub pathway of transcription-coupled repair eliminating
adducts from the transcribed strand of active gene sequences
(18). Interstrand crosslinks are most likely processed by
recombination repair mechanisms (19). The degree of toler-
ance to persisting (unrepaired) DNA lesions determines the
fate of a given cell, which may be survival or apoptosis (2).
The molecular mechanisms underlying resistance in the clin-
ical setting might be decreased adduct formation, increased
adduct repair or enhanced tolerance to cisplatin-induced
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doi:10.1093/nar/gkl051lesions. Owing to the lack of sensitive analytical methods for a
fast and reliable measurement of DNA platination products at
the level of individual cells or in deﬁned gene sequences, the
relative contribution of the different mechanisms for intrinsic
or acquired resistance is far away from being understood.
Furthermore, even the relative importance of the various,
structurally deﬁned DNA adducts for both, the antineoplastic
efﬁciency and the cell type speciﬁc toxicity, are still discussed
controversially.
In order to improve the knowledge about the molecular
mechanisms of cisplatin-related cytotoxicity, numerous
analytical attempts have been made within the past 20
years to detect and measure Pt-DNA adducts in experimental
systems and in clinical specimens. Among these methods are
spectroscopic procedures like NMR (20), atomic absorption
spectrometry (AAS) (21) or inductively coupled plasma mass
spectroscopy (ICP-MS) (22) as well as
32P-postlabeling
techniques (23–25). Further progress in understanding the
molecular mechanisms which modulate the activity proﬁle
of cisplatin in vivo was hampered, because these methods
are not sensitive enough to measure DNA platination at clin-
ically relevant levels (NMR), or are unable to distinguish
between speciﬁc lesions (AAS, ICP-MS), or do not permit
single cell resolution (all methods).
Several attempts were made to quantify DNA platination
products by immuno-analytical assays based on polyclonal
or monoclonal antibodies (26–29). Two different strat-
egies were applied to prepare antigens for this purpose.
Fichtinger-Schepman et al. (20) immunized rabbits with
isolated cis-Pt(NH3)2d(pGpG)) or cis-Pt(NH3)2d(pApG)
molecules. Antisera obtained thereby were capable to recog-
nize the corresponding adducts in a competitive ELISA but
only after a comprehensive nuclease digestion of isolated
DNA followed by chromatographic isolation of the platinated
dinucleotides. First attempt to detect cisplatin-induced DNA
lesions at the single cell level by an immuno-histochemical
assay were based on a polyclonal serum against Pt-DNA (12).
Aiming at an adduct-speciﬁc measurement Tilby et al. (30),
Chao et al. (31) and Sundquist et al. (32) independently gen-
erated monoclonal antibodies against cisplatin-treated DNA.
Until now, however, most attempts failed to characterize these
Mabs for their epitope speciﬁcity in genomic DNA. Recently,
Meczes et al. (33) reported the binding of Mab CP9/19 to
guanine–guanine intrastrand crosslinks. Here, we describe a
new strategy to generate and characterize monoclonal anti-
bodies with deﬁned speciﬁcities for cisplatin-induced DNA
adducts. Furthermore, we have used these Mabs to establish
a quantitative immuno-cytological assay (ICA) which enables
molecular dosimetry studies at the single cell level in experi-
mental systems and in clinical samples.
MATERIALS AND METHODS
In vitro platination of DNA
For immunization of rats, development of ELISA, magneto-
bead based separation of hybridomas and for the character-
ization of Mabs calf thymus DNA (Roche, Mannheim,
Germany) was platinated according to Fichtinger-Schepman
(20). A 1.6 mM stock solution of cisplatin in 150 mM
NaCl (Platinex, Bristol, Mu ¨nchen, Germany) was diluted
with saline to ﬁnal concentrations between 0.05 and 150
mM and incubated with DNA for 12 h at 37 C. The DNA
preparations were puriﬁed by spin column centrifugation
(BioSpin 6; BioRad, Mu ¨nchen, Germany) and the DNA
concentration was quantiﬁed with the SYBR Green-I kit
(Molecular Probes, Eugene). In collaboration with the Institut
fu ¨r Chemo- und Biosensorik (Mu ¨nster, Germany) the molar
content of platinum in DNA was determined according
to Reed et al. (34) by AAS (Perkin-Elmer 4100 ZL;
Perkin-Elmer, Norwalk).
Immunization
The antigen was synthesized according to Tilby et al. (30)
by coupling cisplatin-treated DNA (Pt-DNA; 2100 mg/ml,
188 pmol Pt/mg DNA) electrostatically to methyl-BSA
[2100 mg/ml in phosphate-buffered saline (PBS); Sigma,
Deisenhofen, Germany]. BD IX rats (50 days old; Harlan-
Winkelmann, Borchen, Germany) were immunized by
intraperitonial injections of the Pt-DNA protein complex
(530 mg containing 50 nmol adduct) dissolved in 250 ml
MPL-TDM adjuvants (Sigma, Deisenhofen, Germany). Treat-
ment was repeatedevery 4 weeks and the serum titer of the rats
for anti-(Pt-DNA) antibodies was determined by ELISA meas-
urement (see below) 10 days after injection. Immunized anim-
als with a high titer were sacriﬁced 3 days after the last boost
injection andhybridomaswere established fromspleencellsas
described earlier (35).
ELISA
Antibody activity was determined by an ELISA procedure
according to Sundquist et al. (32). Each well of a 96-well
polystyrol microtiter-plate (Maxisorp, Nunc, Wiesbaden, Ger-
many) was incubated with 200 ml DEAE dextran (100 mg/ml;
Amersham Pharmacia, Freiburg, Germany) in 1 M Na2CO3,
5 mM EDTA, pH 9.6 for 5 h at 37 C. After washing with PBS
wells were coated with untreated DNA or with Pt-DNA (188
pmol Pt/mg), irradiated for cross-linking (0.12 J; UV Strata-
linker 2400, Stratagene, La Jolla), and blocked with casein
(1% in PBS; 1 h; 37 C; Schleicher & Schuell, Dassel, Ger-
many). Per well 50 ml of dilutedserum, hybridoma supernatant
or chromatographic fractions, were incubated (1 h at 37 C).
The antibody activity was detected by an alkaline
phosphatase-labeled sheep anti-(rat Ig) antibody (50 ml/well;
Dianova, Hamburg, Germany), using 1 mg p-nitrophenyl
phosphate/ml (Sigma) in 10 mM diethanolamine, 1 mM
MgCl2, pH 9.8 as substrate. Absorption was measured at
405 nm (micro plate reader ELx 800; Bio-Tek Instruments,
Neufahrn, Germany).
Magneto-bead based isolation of hybridomas
After cell fusion the heterogeneous pools of hybridomas
were selected for cells presenting membrane-anchored anti-
(Pt-DNA) antibodies by a magneto bead technique (36). Mag-
neto beads (four times 108/ml; Type M 450, Dynal, Hamburg,
Germany) were incubated in poly-L-lysine solution (50 mg/ml;
Sigma) for 4 h at 37 C and then coated with Pt-DNA
(1000 mg/ml; 5 pmol Pt/mg; incubation for 4 h at 37 C
followed by 12 h at 4 C). Nonspeciﬁc binding was blocked
with RPMI 1640 medium containing 20% fetal calf serum
(FCS). Hybridoma cells (106) and beads (107) were mixed
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Ossendorp et al. (37) for 15 min at 25 C, followed by a 2 h
incubation at 4 C. Bead-labeled cells were isolated via mag-
netic separation (MPC magnet, Dynal), washed twice with
ice-cold medium, diluted to low concentrations and seeded
into microtiter plates for further cultivation (38).
Cell culture of hybridomas and isotyping of Mabs
After hypoxantine-aminopterin-thymidine (HAT)-selection
hybridomas were cultivated in serum-free medium
(Hybridoma-SFM; Invitrogen, Karlsruhe, Germany). Isotyp-
ing for immunoglobulin subclasses was performed by an
ELISA technique according to Coulter et al., (39) using
isotype speciﬁc anti-(rat-Ig) antibodies (Sigma).
Purification of antibodies
Antibodies were isolated from hybridoma supernatant accord-
ing to Hutchens and Porath (40) by hydrophobic interaction
chromatography on T-gel (Pierce, Rockford, USA) and
subsequent protein G column chromatography (HiTrap
Protein G; Amersham Pharmacia, Freiburg, Germany).
Antibody concentration was measured by a ‘Capture
ELISA’ technique according to Fleming and Pen (41),
antibody activity by the ELISA described above.
Adduct specificity of Mabs
The adduct-speciﬁcity of a given anti-(Pt-DNA) Mab was
determined by measuring the relative adduct content in
DNA fragments captured by this Mab in a ﬁlter binding
assay. Brieﬂy, calf thymus DNA was reacted with different
concentrations of cisplatin (see above) resulting in fractions
containing 0.52 (Pt 1), 1.01 (Pt 2) or 5.02 (Pt 3) pmol Pt/mg
DNA. Fractions were adjusted to 50 mM Tris–HCl, 100 mM
NaCl, 1 mM EDTA, pH 7.5 (STE buffer) and the DNA was
fragmented by ultrasonic treatment (Soniﬁer B 12, Branson;
ﬁve times 1 min on ice) to a medium length of 500 bp as
determined by agarose gel electrophoresis. Aliquots of 50 mg
DNA in 60 ml STE buffer containing 500 mg BSA/ml were
mixed with 100 mg (in 40 ml STE) of the monoclonal anti-
(Pt-DNA) antibody to be characterized and incubated for 12 h
at 4 C. Mab-complexed DNA was separated from unbound
DNA fragments by soaking the solution through nitrocellulose
ﬁlters (2 · 2 cm; Protran BA 85, Schleicher & Schuell, Dassel,
Germany). The captured DNA fragments were recovered from
the Mab–DNA complexes by agitating the membranes in
small volumes of elution buffer (5 mM Tris–HCl, 0.1 mM
EDTA, 5% butanol, pH 7.5) for 48 h at 25 C. The eluate was
concentrated, desalted by gel ﬁltration (BioSpin 6, BioRad,
Mu ¨nchen), and the DNA content was measured ﬂuorimetric-
ally (SYBR Green I kit; Molecular Probes, Leiden, ND).
Digestion of isolated DNA fragments, chromatographic
separation of platinated dinucleotides, chemical deplatination,
32P-postlabelingandhigh-performanceliquidchromatography
separation of labeled dinucleotides were performed essentially
as described earlier (25) with some modiﬁcations: 50 mg (in
50 ml) of each Mab-selected DNA-fraction were digested by
adding 6 U of nuclease P1 (Roche) and incubated for 2 h at
55 C. After conditioning with 10 ml of 1 M Tris–HCl, 10 mM
MgCl2, 1 mM ZnCl2, pH 8.2 digestion to nucleotides was
continued by adding 100 U DNAse (2 h at 37 C; Roche)
and subsequent treatment with 20 U alkaline phosphatase
(2 h at 37 C; Roche). Enzymes were inactivated (100 C,
5 min) and removed by extraction with an equal volume of
phenol/chloroform/isoamylethanol (25/24/1, v/v). Traces of
phenol were removed by extraction with an equal volume
of chloroform. The platinated dinucleotides were separated
from the unmodiﬁed mononucleosides by strong cation-
exchange chromatography using SCX solid phase extraction
cartridges (Lichrolut SCX, 200 mg; Merck, Darmstadt, FRG)
and a vacuum manifold. Cartridges were equilibrated with
1 ml of Tris–HCl (50 mM, pH 3) and the DNA digests
were adjusted to pH 3 by HCl prior to loading. Non-adducted
nucleosides were eluted by Na-formate (5 mM, pH 6; eight
times 1 ml) followed by elution of the platinated products with
NH4OH (250 mM; 1 ml). This fraction was spiked with
300 fmol dTpdT (Sigma) as internal standard. Samples
were dried in vacuo, the residues were dissolved in 12 ml
NaCN (100 mM) and incubated for 2 h at 65 C to deplatinate
the Pt-dinucleotides. Then, samples were adjusted to pH 8
by addition of 7 ml of 3 M Na-acetate solution. External stand-
ards were prepared from authentic dApdG and dGpdG
dinucleotides (100 fmol each).
The 50-
32P-postlabeling of dinucleotides was catalyzed by
2.5 U polynucleotide kinase (Roche), using 1.65 pmol
[g-
32P]ATP (3,000 Ci/mmol; 10 mCi/ml; Amersham Pharma-
cia).After overnight incubationatRTthevolumewasadjusted
to 150 ml with H2O and the molar content of labeled dinuc-
leotides was determined by radio-chromatography. Of each
sample 50 ml was applied on a heated Inertsil ODS-80A C-
18 column (particle size: 5 mm; dimension: 4.6 · 150 mm;
Phase Separations, Waddinxveen, ND) coupled to an on-line
radioisotope detector (Radiomatic 500TR ﬂow scintillation
analyzer, Canberra Packard, Meriden). Products were separ-
ated by isocratic elution (100 mM KH2PO4/4.5% MeOH, pH
5.5; ﬂow: 1 ml/min; 40 C) over a period of 16 min. Simul-
taneous Cerenkow radiation and absorption at 260 nm was
measured every 6 s.
Immuno-cytological assay
Cells were cultured on microscopic slides, and washed with
a starch solution (HAES-steril, Fresenius, Bad Homburg,
Germany; 25% in PBS). Tissue sections and cell suspensions
were placed onto pre-coated slides (ImmunoSelect, Squarix,
Germany). All slides were air-dried and stored at  80 C until
further processing.
The immunostaining of DNA adducts was performed essen-
tially as described elsewhere (42) with some modiﬁcations.
Brieﬂy, samples were ﬁxed in methanol ( 20 C; 12 h) and
rehydrated in PBS (10 min; 25 C). Each of the next steps was
followed by washing with PBS. Cellular RNA was digested by
RNase treatment (RNase A, 200 mg/ml; RNase T1, 50 U/ml in
PBS; 100 ml per slide; Roche; 1 h; 37 C) in a humidiﬁed
chamber. Nuclear DNA was partly denatured by mild treat-
ment with alkali (70 mM NaOH, 140 mM NaCl, 40% meth-
anol v/v; 5 min at 0 C), and cellular proteins were removed by
a two-step proteolytic procedure: Samples were ﬁrst digested
with prewarmed pepsin (Roche; single cells, kidney and liver
sections, 200 mg/ml; gastric mucosa, 1000 mg/ml in 20 mM
HCl) for 5 min (cells) or 10 min (tissues) at 37 C, and
then with prewarmed proteinase K (cells, 2 mg/ml, tissues,
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for5min(cells) or10min(tissue) at37 C.Afterblocking with
casein (1% in PBS; 30 min; 25 C) slides were incubated with
anti-(Pt-DNA) Mabs (0.1 mg/ml in PBS containing 1% casein
and 200 mg of sonicated calf thymus DNA/ml; 2 h; 37 C).
After washing (0.05% Tween 20 in PBS; 2 min; 25 C) a
three-step sandwich immunostaining was performed by sub-
sequent incubation with: (i) FITC-labeled goat anti-(rat Ig)
(Dianova, Hamburg, Germany; 6.5 mg/ml in PBS, 1% casein;
45 min; 37 C), (ii) ALEXA FLUOR 488-labeled rabbit anti-
(FITC) (5 mg/ml in PBS, 1% casein; 45 min at 37 C; Molecu-
lar Probes) and (iii) ALEXA FLUOR 488 goat anti-(rabbit Ig)
(5mg/mlinPBS,1%casein;45min,37 C;MolecularProbes).
Finally, the nuclear DNA was counterstained with DAPI
(1mg/ml in PBS; 30 min; 25 C; Serva, Heidelberg, Germany)
and cells were covered with Vectashield densiﬁcation
compound (Vector Laboratories, Burlingame).
Image analysis
Visualization and measurement of antibody- and DNA-
derived ﬂuorescence was performed by a microscope-coupled
digital image analysis system (ﬂuorescent microscope
Axioplan, lens Plan-Neoﬂuar 40·/0,75; mercury lamp HBO
100 W; DAPI ﬁlter, excitation 365 nm, emission 397 nm;
FITC/ALEXA 488 ﬁlter, excitation 450–490 nm, emission
515–565 nm, Zeiss, Go ¨ttingen, Germany; charge-coupled
device camera C4880, Hamamatsu Photonics, Herrsching,
Germany; ACAS 6.0 Cytometry Analysis System, ACAS
II, Dunn, Asbach, Germany). The nuclear DNA of single
cells was localized and measured by the DAPI-derived signals
and those pixels were scanned in parallel for antibody-derived
ALEXA ﬂuorescence. Integrated ALEXA signals from each
nucleus were corrected for the corresponding DNA content
and computed for at least 100 cells per slide.
Cisplatin treatment of cultivated cells
Jurkat cells (human T cell leukemia line; TIB-152; ATCC,
Rockville) were cultivated in RPMI 1640 medium supplemen-
ted with FCS (10%), L-glutamine (2 mM) and penicillin
(100 mg/ml) in a humidiﬁed atmosphere (5% CO2,3 7  C).
Exponentially growing cells were exposed to various concen-
trations of cisplatin (0.5–10 mg/ml) for 2 h at 37 C. After
washing, cells were transferred to fresh medium, further
incubated for 1 h at 37 C, spun down and resuspended in
PBS containing 25% starch solution (see above). Cells were
placed on precoated microscopic slides and analyzed by ICA
measurement (see above).
Cisplatin treatment of mice
Formation and repair of Pt-DNA adducts in vivo was measured
in tissues or cells from male C57Bl/6 mice (age, 20 weeks;
Harlan-Winkelmann, Borchen, Germany) treated with a single
intraperitonial dose of cisplatin (Platinex, Bristol; 2 or 10
mg/kg body weight; untreated controls: sterile saline). XPC
knockout mice were kindly provided by Dr Leon Mullenders,
University of Leiden, ND. Animals were sacriﬁced at various
time points after application by CO2. Tissue samples were
shock frozen in liquid nitrogen and cryo-sections (8 mm)
were prepared using a Frigocut 2800 (Reichert-Jung, Nußloch,
Germany). T lymphocytes were isolated from heparinized
peripheral blood (250 ml) by magneto beads coated with
mouse pan T (Thy 1.2) antibodies (Dynal) according to the
manufacturer’s protocol. Beads were detached from isolated
cells by trypsinization (15 min; 37 C; inactivation with FCS)
and removed magnetically. Bead-free T cells were applied to
microscopic slides as described above.
Human lymphocytes and bioptic material
Blood samples and bioptic specimens were kindly provided
by Drs U. Vanhoefer and W. Eberhardt, Department of
Internal Medicine (Cancer Research) West German Cancer
Center Essen. Samples were taken from patients with gastric
cancer before or after monotherapy with cisplatin (infusion
time 1 h; Platinex, Bristol). T cells were isolated from
heparinized peripheral blood (500 ml) by immuno-magnetic
separation using anti-(CD2) coated beads (CD2 collection
kit, Dynal) according to the manufacturer’s protocol and
bead-free T cells were applied to microscopic slides (see
above). Biopsies of the primary tumor and of non-malignant
adherent tissue were obtained endoscopically 48 h after
administration of cisplatin and were frozen immediately in
liquid nitrogen. Cryo-sections (8 mm) were prepared and
mounted on slides (see above). Serial sections were alternat-
ively immuno-stained for DNA adducts (ICA) or by
Haematoxylin-Eosin (HE).
Data analysis
In all mouse experiments two treated and one control animal
were used per time point and 50 sections were prepared from
each organ. Per tissue sample 10 sections were chosen
at random and analyzed by ICA. In total a minimum of
100 cells of each cell type per animal were analyzed. ‘Sigma-
Plot 4.0’ software (Jandel Scientiﬁc, Erkrath, Germany)
was used to calculate Pt-DNA adduct levels from integrated
image signals. The results are given in relative units (mean ±
SD or SE).
RESULTS AND DISCUSSION
Experimental design
In case of cisplatin-induced DNA lesions the two ‘classical’
methods to establish adduct-speciﬁc antibodies for immuno-
histochemical detection of DNA damage have failed (see
above). This indicates that the stereochemical motif recog-
nized by antibodies against cisplatin adducts is completely
different in small di- or oligonucleotide molecules in compar-
ison with long chain genomic DNA.
Therefore, we have approached the generation of adduct-
speciﬁc Mabs for single cell analysis by an alternative strategy
comprising four major steps: (i) immunization of rats with
highly adducted genomic DNA to provoke a broad immune
response; (ii) selection for hybridoma clones producing Mabs
with high binding afﬁnity to low adducted DNA; (iii) ‘retro-
spective’ characterization of the binding speciﬁcity of indi-
vidual Mabs by immuno-trapping of DNA fragments carrying
recognized adducts, followed (iv) by the chromatographic
identiﬁcation of the trapped Pt-lesion(s). Finally, Mab clones
with deﬁned speciﬁcity were screened for their applicability in
a quantitative ICA.
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For the generation and the characterization of suitable
Mabs calf thymus DNA was reacted with different concentra-
tions of cisplatin and the absolute content of platinum in the
samples was determined by AAS (Table 1). To achieve a
sufﬁcient immune response against cisplatin adducts it is
necessary to vaccinate rodents with highly Pt-DNA (27).
The optimal adduct concentration for this purpose was
determined to be 1 per 5 nt for mice (31) and 1 per 125 nt
for rats (30). In this study we have immunized BD IX rats with
cisplatin-reacted DNA (1 adduct/16 nt) coupled to
methyl-BSA. Serum titers of anti-(Pt-DNA) antibodies were
determined by a non-competitive ELISA using Pt-DNA as
binding substrate.
After a cumulative dose of 350 nmol Pt adducts per animal
spleen plasma cells were fused with ‘Y123’ rat myeloma cells.
To enrich the resulting hybridoma populations for antibodies
which can recognize Pt adducts at low frequencies in DNA we
used an immuno-magnetic separation technique (37,43). This
method applying magneto beads coated with low-adducted
DNA (‘Pt-1’; 1 adduct/640 nt, see Table 1) selects for cell
clones producing high afﬁnity antibodies due to their stronger
binding to the beads (44,45) and excludes Mabs which
recognize stereochemical artifacts in highly adducted DNA.
In comparison with the original hybridoma pool this pre-
selection step led to a tenfold increase in ELISA-positive
clones.
Adduct specificity of anti-(Pt-DNA) Mabs
As cisplatin-reacted DNA harbors a variety of distinct adduct
structures (see above) in different sequence neighborhoods the
heterogeneity of a Pt-DNA antigen provokes an immune
response encompassing antibodies of different speciﬁcity.
To characterize the binding motif of a given Mab clone we
have designed a new experimental approach to determine the
epitope speciﬁcity of monoclonal antibodies directed against
structuralmodiﬁcationsingenomic DNA(Figure1).Thebasic
idea of this method is to pull out from a large pool of DNA
molecules just the fraction containing the modiﬁcation(s)
which are recognized by the antibody. A prerequisite for
such an immuno-trapping strategy is a sufﬁciently low adduc-
ted DNA substrate carrying as mean less than one lesion per
molecule.
Table 1. Properties of cisplatin-reacted calf thymus DNA used for the char-
acterization of anti-(Pt-DNA) monoclonal antibodies
DNA preparation Pt 1 Pt 2 Pt 3
Cisplatin exposure (mM) 0.15 0.30 1.50
Platinum in DNA (pmol/mg)
a 0.52 1.01 5.22
Nucleotides/Pt adduct 6250 3333 625
Adducts/500 bp fragment
b 0.16 0.30 1.60
% of all 500 bp fragments carrying
cisplatin adducts
c
17 25 80
% of all adducted 500 bp fragments
carrying
1 adduct 92 86 41
2 adducts 7 12 32
3 adducts 1 3 17
4 adducts 0 1 6
5 adducts 0 0 3
6 adducts 0 0 2
aAs determined by AAS measurement.
bAssuming a random distribution of adducts in DNA.
cCalculated according to a Poisson distribution.
- Pt-DNA
- detachment of Mab-trapped fragments
- ultrasonic fragmentation (~500 bp)
anti-Pt-(GG) Mab
Pt-(AG) Pt-(GG) G-Pt-G
- binding of Pt-DNA Mab complexes on nitrocellulose
- elution of unbound Pt-DNA
- enzymatic digestion of Pt-DNA to nucleotides
dN, Pt-d(GpG)
- cation-exchange chromatography dN
Pt-d(GpG)
-5 ´ -[32 P] labeling of dinucleotides
d(32pGpG)
- HPLC / radioisotope detector
- deplatination of Pt-dinucleosides
d(32pApG) d(32pGpG)
c
p
m
External standard Sample
- incubation with Mab
Figure 1. Schematic diagram of immuno-trapping and
32P-postlabeling pro-
cedures to determine the binding specificity of anti-(Pt-DNA) monoclonal
antibodies.
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average size of 500 bp were prepared by ultrasonic treatment
of Pt-DNA preparations ‘Pt 1’, ‘Pt 2’ and ‘Pt 3’ (Table 1).
Assuming a random distribution of platination products, the
mean number of Pt adducts per DNA molecule was calculated
to be 0.16 (Pt 1), 0.3 (Pt 2) and 1.6 (Pt 3), respectively.
According to the Poisson distribution, the percentage of
adducted fragments carrying just one lesion was 92, 86 and
41% in the respective samples.
When these DNA substrates were incubated with antibodies
to be characterized and passed through nitrocellulose
membranes, only protein (Mab)-complexed double-stranded
DNA molecules were retained. Filter-bound DNA fragments
harboring the selected epitope(s) were then recovered from
the membranes (Materials and Methods). As shown earlier,
both separation steps, binding and elution of adducted DNA
fragments, can be performed in a quantitative manner with
efﬁciencies of >90% (46).
To identify the Mab-trapped modiﬁcations we have
analyzed the eluted DNA fractions by a
32P-postlabeling
assay (25). When the DNA was digested enzymatically to
mononucleosides Pt-GG and Pt-AG dinucleotides remained
uncleaved and could be isolated chromatographically. After
chemical deplatination and
32P-postlabeling the dinucleotides
were measured by radiochromatography. The identity of
radioactive peaks was conﬁrmed by co-application of authen-
tic GG and AG dinucleotides in the procedure. Thereby, it was
possible to determine the relative concentrations of Pt-(GG)
and Pt-(AG) residues in the immuno-trapped DNA samples.
Adduct analysis of the unselected DNA substrates ‘Pt 1’,
‘Pt 2’ and ‘Pt 3’ exhibited relative contents of Pt-(AG) and
Pt-(GG) of about 13–14% and 86–87%, respectively, inde-
pendently from the original degree of platination
(Figure 2A). This ﬁnding is in good agreement with data in
the literature (20) and underlines the reproducibility and
validity of the analytical procedure.
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Figure 2. Radio-chromatographic analysis of the relative amounts of Pt-(GG) and Pt-(AG) intrastrand crosslinks in DNA preparations Pt 1–3 without antibody
selection(A)oraftertheimmuno-trappingprocedurewithMabR-B3(B),MabR-C7(C)orMabR-C18(D).They-axesrepresentthe
32P-derivedradioactivesignals
(c.p.m.), the x-axes give the elution time (min).
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binding preference of Mab ‘R-B3’ for Pt-(AG) adducts in
DNA (Figure 2B). In substrate ‘Pt 1’, containing the lowest
adduct level, the relative amount of Pt-(AG) was increased
by immuno-trapping from 13% in unselected DNA to
nearly 50%. Taking into account that 8% of the ‘Pt 1’-
fragments carried more than one lesion (most likely additional
GG-adducts, see below and Table 1) and assuming a linear
inﬂuence of the antibody binding during the selection step
it can be estimated that Mab ‘R-B3’ has an at least four-fold
higher afﬁnity to Pt-(AG) as compared with Pt-(GG) in
genomic DNA. The enrichment effect for the AG dinuc-
leotides was less pronounced in the higher adducted substrates
‘Pt 2’ and ‘Pt 3’ (45 and 26% of AG, respectively). This
observation can be attributed to the co-isolation of the
6.5 times more frequent Pt-(GG) lesion occasionally located
on the same DNA molecule as 16% (Pt 2) and 60% (Pt 3) of
those substrate molecules carried more than one adduct
(Table 1).
A second Mab, ‘R-C7’ (Figure 2C) did not discriminate
between Pt-(GG) and Pt-(AG) intrastrand lesions despite of
its high afﬁnity to cisplatin-reacted DNA as measured in
ELISA and ﬁlter binding assays. The relative adduct distri-
bution (13% AG; 87% GG) in the antibody-trapped
DNA fractions was exactly the same as in the unselected
substrate, independently from the initial degree of platination.
This might indicate that both major interstrand cross-
links share a common structural motif in genomic DNA
which is recognized by ‘R-C7’. Thus this antibody is a
useful tool for the simultaneous detection of both cisplatin
adducts.
Finally, Mab ‘R-C18’ was found to enrich the proportion
of Pt-(GG) lesions by immuno-trapping to 96% in substrate
‘Pt 1’, to 93% in ‘Pt 2’ and to 91% in ‘Pt 3’ (Figure 2D).
Indicating a high speciﬁcity of this antibody for the major
DNA adduct. In this case the ‘leveling effect’ caused by frag-
ments harboring more than one lesion in higher Pt-DNA was
less pronounced. For statistical reasons the identity of
co-isolated epitopes on the same fragment is most likely
also Pt-(GG).
Taking together the results demonstrate the potency of
our new method to determine the epitope-speciﬁcity of
monoclonal antibodies raised against complex hapten
structures in genomic DNA. In addition, the immune response
in this approach is not restricted to adducts in a given
sequence context as in synthetic oligonucleotide haptens
and the hybridoma enrichment step selects for high
afﬁnity antibodies with a broad spectrum of binding
characteristics.
Further characterization of the newly established Mabs
conﬁrmed earlier observations (29) that antibodies binding
to cisplatin-induced adducts in native long chain DNA
often have no afﬁnity to these lesions in comparatively
small molecules. When the Mabs were tested in a competitive
ELISA synthetic 32mer single or double-stranded oligonuc-
leotides harboring site speciﬁc Pt-(GG) or Pt-(AG) lesions
showed no inhibitory effects (data not shown). This situation
seems to be different for the monoclonal antibody CP9/19
which was recently characterized to be speciﬁc for Pt-(GG)
adducts (33).
ICA for the visualization and measurement of
cisplatin induced DNA adducts in the
nuclei of individual cells
Mabs characterized for their binding speciﬁcity were further
selected for the applicability in the ICA technique (42) which
allows the quantiﬁcation of DNA adducts at the single cell
level. Nonspeciﬁc antibody binding was minimized by sub-
jecting cells or tissue sections on microscopic slides to pro-
teolytic treatment prior to the immunostaining. Cell loss
during this step was avoided by using pre-coated adhesion
slides (see above).
The sensitivity of the ICA procedure was further augmented
by a multi-step ‘sandwich’ staining using FITC- and ALEXA
488-labeled secondary antibodies, followed by counter-
staining with DAPI for nuclear DNA. Position, area and
intensities of signals from individual cell nuclei were visual-
ized by ﬂuorescence microscopy and recorded by an image
analysis system. Antibody-derived signals were normalized
for the actual DNA content of a given cell and expressed as
arbitrary ﬂuorescence units (AFU).
The complete penetration of the antibodies and the homo-
geneous immuno-staining of the nuclear DNA by the ICA
procedure were veriﬁed by tomography and 3D laser-scanning
microscopy of cisplatin-treated cells (data not shown).
The sensitivity and the range of linearity of the ICA pro-
cedure were examined in a dose response experiment using the
Mabs R-C18 [speciﬁc for Pt-(GG)] or R-C3 [speciﬁc for
Pt-(AG)] to analyze cisplatin-exposed cultured human Jurkat
T cells. The quantitative evaluation of ﬂuorescence signals
from DNA and antibody staining revealed a nearly linear
correlation (r
2 ¼ 0.94 and r
2 ¼ 0.90) between drug concen-
tration and the corresponding apparent levels of Pt-(GG) and
Pt-(AG) DNA adducts, respectively (Figure 3). Both intra-
strand crosslinks could be quantiﬁed by ICA analysis in the
nuclear DNA of Jurkat cells exposed to cisplatin concentra-
tions as low as 0.5 mg/ml.
Formation and processing of Pt-(GG) adducts in
different cell types of cisplatin-treated mice
Techniques which depict DNA lesions at the level of indi-
vidual nuclei are particularly important for the analysis of
tissue sections as they are usually composed of different
cell types. Therefore we have adapted the ICA technique to
measure formation and repair kinetics of Pt-(GG) DNA
adducts in cryo-sections from tissues of C57Bl/6 mice sacri-
ﬁced at different time points after cisplatin treatment. As
severe nephrotoxicity is one of the dose limiting side effects
of cisplatin (6,47) we have immuno-stained kidney cells of
exposed und untreated mice (Figure 4A). In comparison to
very low background signals in the control tissue the ICA
images showed that the nuclear DNA of all renal cells was
highly adducted 24 h after drug application with distinct
intercellular variations. The epithelial cells of kidney tubuli
(tubuli recti proximalis) displayed a much brighter
immuno-ﬂuorescence staining than all other cell types of
this tissue. The ACAS image analysis system used here
allowed the differential measurement of selected cell nuclei
within a given tissue section demonstrating the analytical
power of the single cell measurement: (Figure 4B). The
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revealed 50% higher adduct levels in the tubular cells
when compared with the surrounding cortex cells (1.45 versus
0.95 AFU 24 h after cisplatin;P < 0.05, paired t-test; Figure 5).
The relative differences between these two cell types
were even more pronounced in mice sacriﬁced 2 weeks
after cisplatin exposure (Figure 4A). At this time cortex
and distal tubular cells had eliminated the majority of the
initially formed Pt-(GG) adducts whereas the nuclear DNA
of proximal tubuli epithelia still contained a burden of lesions
comparable to the maximum adduct level in cortex cells at day
one after treatment. The high degree of DNA platination in
the tubular cells is most likely caused by the augmented
intratubular concentration of free cisplatin during renal
clearance in combination with a slightly acidic environment
within the tubules, favoring the formation of reactive drug
intermediates (48).
Quantitative ICA measurement of tissue sections and blood
lymphocytes from cisplatin-treated mice revealed a broad
range of peak adduct levels in different cell types
(Figure 5). Compared with tubular epithelial and cortex
cellsof the kidneywhere Pt-(GG) adducts reached a maximum
of 1.82 and 1.15 AFU, respectively, the cells in liver sections
exhibited a rather homogeneous immunostaining with a peak
value of 0.80 AFU 12 h after treatment. In contrast,
cisplatin-induced DNA damage in peripheral T lymphocytes
of the same mice was about six and three times lower than in
kidney tubular epithelia and in liver cells, respectively.
Pt-(GG) adduct levels culminated at 0.25 AFU 8 h after
drug application. Similar observations of a comparatively
low DNA platination in white blood cells after cisplatin expos-
ure in vivo or in vitro have been made earlier (49). Whether
this is caused by pharmacokinetic factors like reduced inﬂux,
accelerated export or intracellular modiﬁcation of the drug or
by a more efﬁcient repair of DNA platination products in T
lymphocytes remains open.
To calibrate the relative adduct values based on ICA meas-
urement for the absolute number of cisplatin-induced lesions
percellnucleuswe have determinedbyAAS themolarcontent
of platinum in DNA isolated from the same mouse tissue.
Assuming that Pt-(GG) accounts for about 75% of the total
DNA platination the peak formation level of this adduct after a
dose of 10 mg cisplatin/kg body weight was calculated to be
 800000, 600000 and 200000 per cell in mouse kidney, liver
and T lymphocytes, respectively. The lowest adduct level
reproducibly measured was in mouse lymphocytes 2 weeks
after drug treatment, corresponding to 25000 Pt-(GG) lesions
per nucleus.
Peak adduct levels were reached between 8 and 12 h after
cisplatin application in all cell types analyzed here. This rather
delayed accumulation of DNA crosslinks in vivo is probably
due to a stepwise mobilization of the drug from plasma protein
binding (50) and to the slow conversion of initially formed
monoadducts to the bivalent crosslinks detected by the ICA
measurement (51). The shapes of the Pt-(GG) repair kinetics
were basically similar in all four cell types. After a period of
fast repair where about 50–70% of the initially formed lesions
were removed within 2–6 days the adduct levels reached a
nearly stable plateau. Until day 15 only a minor fraction of the
remainingPt-(GG)lesions was removed inaddition(Figure5).
Whetherthepersistingadductsatthistimewerelessaccessible
forthecellularDNArepairsysteme.g.owingtotheirsequence
context remains to be elucidated.
To further demonstrate the analytical power of adduct-
speciﬁc ICA measurement we have compared the formation
and repair of the Pt-(GG) lesion in speciﬁc cell types of mice
proﬁcient or deﬁcient for NER. Kidney tubular epithelium
cells of NER knockout (XPC
 / ) mice exposed to a low
dose of cisplatin (2 mg/kg body weight) exhibited higher
accumulation and complete persistence of this adduct in com-
parison to corresponding wild type cells with intact global
genomic NER (Figure 6). Thus, the newly established immun-
oassay now allows the systematic in vivo analysis of adduct
processing and drug-induced cytotoxicity in speciﬁc cells of
transgenic or knockout mouse strains.
ICA measurement of Pt-DNA adducts as a tool for
single cell dosimetry in clinical samples
Finally we have tested, whether the ICA procedure is sensitive
enough to measure deﬁned adducts in clinical specimens.
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Figure 3. Correlation between the dose of cisplatin (exposure: 2 h; 37 C) and
the level of specific intrastrand crosslinks in the nuclear DNA of cultivated
human Jurkat T cells. Adduct levels were measured after immunostaining with
anti-(Pt-DNA) Mab R-C18 (Pt-[GG] lesions (A), or R-B3 specific for Pt-(AG)
(B) and quantitative ICA image analysis (Materials and Methods). Antibody-
derived signals from individual nuclei were normalized for the actual DNA
content of each cell. Values are given as AFU and represent means± SE of 200
analyzed cells per dose. Correlation: (A) r
2 ¼ 0.96; (B) r
2 ¼ 0.91.
e47 Nucleic Acids Research, 2006, Vol. 34, No. 6 PAGE 8 OF 12Biopsies from three patients with advanced gastric cancer who
had received a single infusion of cisplatin (30 or 50 mg/m
2)
were included in this pilot experiment. Samples from tumor
areas and from adjacent normal tissue were taken before and
48 h after cisplatin infusion. Serial sections of post-treatment
normal gastric mucosa stained either for histological exam-
ination with HE or for ICA analysis with DAPI and Mab
R-C18, demonstrated the applicability of this procedure
(Figure 7A). Similar to the mouse experiments a very high
adduct-speciﬁc staining was observed in post-treatment biops-
ies when compared with control biopsies prior to treatment
(Figure 7B). Furthermore, higher magniﬁcation revealed dis-
tinct intercellular heterogeneities of DNA adduct levels within
the same tissue section which may result from cell type spe-
ciﬁc formation and repair rates for Pt-(GG) adducts in vivo.
This observation again underlines the importance of single cell
analysis especially in clinical specimens and the necessity to
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Figure5.FormationandrepairofPt-(GG)intrastrandDNAadductsindifferent
cell types of mice after cisplatin exposure. Male C57Bl/6 mice (age 20 weeks)
were sacrificed before (t0) or at various time points after a single injection of
cisplatin (10 mg/kg, intraperitonial; two animals per time point) and tissues
were stored in liquid nitrogen. Blood T lymphocytes and frozen tissue sections
(8mm)werepreparedasdescribedandPt-(GG)adductlevelsweremeasuredby
ICA analysis using Mab R-C18 (Figures 3 and 4). Values are means (±SE) of
200 measured cells per time point: A, kidney, epithelial cells of tubules prox-
imalis; B, kidney cortex cells without tubules proximalis; C, liver cells; D,
peripheral T lymphocytes. For a given time point adduct levels were signifi-
cantly different (paired t-test: P < 0.05) between cell/tissue types A–D except
for the comparison of B and C between days 5 and 15.
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Figure 6. High accumulation and complete persistence of Pt-(GG) adducts
in the DNA of kidney tubular epithelium cells of mice deficient for NER
(XPC
 / ).XPC
+/+(wild-type,closedsquares)andXPC
 / mice(opencircles)
were treated with a single dose of cisplatin (2 mg/kg body weight, intraper-
itonial) and kidney tissue sections were analyzed for DNA adduct levels as in
Figure 5. Adduct levels were significantly different (paired t-test: P < 0.05)
between both strains for time points >12 h.
AB
15 d Untreated 24 h
100 µm
DNA
IF
15 d
After Cisplatin
Figure 4. Visualization of Pt-(GG) intrastrand adducts in the DNA of individual mouse kidney cells by immunostaining). Male C57Bl/6 mice received a single
injection of cisplatin (10 mg/kg intraperitonial; untreated controls, 150 mM NaCl) and were sacrificed 24 h or 15 days later. Cryo-sections of kidney tissue were
stainedforDNAwithDAPI(blue)andforPt-(GG)inDNAbysandwich-immunostainingusingMabR-C18(green;seeMaterialsandMethods).(A)Micrographsof
DNAandimmuno-fluorescence(IF)ontissuesectionsfromuntreatedortreatedanimals,(B)ICAimageanalysisoffluorescence-stainedkidneycells(15daysafter
cisplatin).CellnucleiwerelocalizedbyDNA-DAPIsignalsand co-localizedantibody-derivedsignalswere recordedbythe ACASimageanalysissystem.Specific
cell types (e.g. tubulus epithelial cells marked in red) can be evaluated separately.
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quantitative evaluation of the immunostained biopsies indic-
ated a dose dependency of adduct levels 48 h after treatment
(Figure 7C). The mean Pt-(GG) values in tissue sections from
patient 1 who received 30 mg cisplatin/m
2 were signiﬁcantly
lower both in the tumor and in adjacent normal gastric mucosa
than the adduct burden in biopsies from patients 2 and
3 (50 mg/m
2).
To compare adduct levels in tumor site biopsies and in
easily accessible cells of the same individual we have
isolated normal T lymphocytes from the peripheral blood of
patients at different time points after treatment. ICA
anaysis of Pt-(GG) levels revealed very homogeneous
antibody-derived signals within a given cell sample
(Figure 8) and steadily increasing adduct levels between
1 and 48 h after cisplatin-infusion (data not shown) indicating
that inthis patient the ongoing formation of Pt-(GG) crosslinks
is still dominating the efﬁciency of DNA repair processes.
Similarly to our ﬁndings in mice, the rate of adduct formation
in peripheral T lymphocytes of patients was markedly lower
than in other cell types e.g. of the gastric mucosa. Again, the
underlying pharmacokinetic and/or biochemical mechanisms
are still unknown. Owing to the small number of patients
included in this study it could not be decided yet whether
the measurement of speciﬁc DNA platination products in
blood-derived cells can serve as a surrogate marker for the
adduct burden of tumor cells as has been suggested earlier
(26,52).
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Figure 7. (A) Visualization of cisplatin-induced adducts in the nuclear DNA of stomach tissue cells from a patient treated for gastric cancer. Biopsies were taken
48 h after infusion of cisplatin (50 mg/m
2) and serial cryo-sections were alternatively stained with HE for morphology or by the ICA procedure for nuclear DNA
(DAPI) and Pt-(GG) adducts (IF) using Mab R-C18. (B) Micrographs of ICA-stained cryo-sections of gastric tissue obtained before or 48 h after cisplatin
treatment. Biopsies were taken both from the tumor and from adjacent normal tissue. DNA, DAPI-staining; IF, Pt-(GG)-specific immunostaining. (C) ICA-
measurementofPt-(GG)adductlevelsincellnucleiofgastrictissuefromthreepatientstreatedwitha singledoseofcisplatin(patient1,30mg/m
2; patients2and3,
50 mg/m
2). A, biopsy before treatment; B, normal tissue 48 h after infusion; C, tumor cells 48 h after infusion. Columns represent mean values (±SE) of 100 cells
selected at random.
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